AbCellera Q2 2022 revenue rises to $46M, net loss widens to $7M; 4 new program starts

AbCellera Biologics Inc.

2022-Q2 EPS reported $0.52 revenue$362,497,000

Total revenue $45.9M, up 66% from $27.6M in Q2 2021; royalties from bebtelovimab contributed $33.2M.
Net loss $6.8M ($0.02/share) vs loss $2.3M ($0.01/share) in prior year, driven by higher R&D and G&A investments.
Added 4 program starts in Q2, cumulative 88 (+47% YoY); total programs under contract 164 (+19% YoY).
Six molecules cumulatively advanced to clinic, up from 4 at Q2 2021.
Cash & marketable securities $1.022B; R&D expenses $26.7M (+78% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.